BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 28583380)

  • 21. Impact of prophylactic cranial irradiation timing on brain relapse rates in patients with stage IIIB non-small-cell lung carcinoma treated with two different chemoradiotherapy regimens.
    Topkan E; Parlak C; Kotek A; Yuksel O; Cengiz M; Ozsahin M; Pehlivan B
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1264-71. PubMed ID: 22172902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [When Should We Perform Surgery for N2 Lung Cancer?;Induction Chemoradiotherapy or Surgery for Local Recurrence or Residual Tumor after Definitive Chemoradiotherapy].
    Ito H; Nakayama H
    Kyobu Geka; 2018 Apr; 71(4):290-299. PubMed ID: 29755103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Technical advancement improves survival in patients with locally advanced non-small cell lung cancer (LA-NSCLC) receiving definitive radiotherapy].
    Wang JB; Jiang W; Ji Z; Cao JZ; Liu LP; Men Y; Xu C; Wang XZ; Hui ZG; Liang J; Lyu JM; Zhou ZM; Xiao ZF; Feng QF; Chen DF; Zhang HX; Yin WB; Wang LH
    Zhonghua Zhong Liu Za Zhi; 2016 Aug; 38(8):607-14. PubMed ID: 27531481
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Salvage surgery for locoregional recurrence or persistent tumor after high dose chemoradiotherapy for locally advanced non-small cell lung cancer.
    Dickhoff C; Dahele M; Paul MA; van de Ven PM; de Langen AJ; Senan S; Smit EF; Hartemink KJ
    Lung Cancer; 2016 Apr; 94():108-13. PubMed ID: 26973215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume.
    Feng W; Zhang Q; Fu XL; Cai XW; Zhu ZF; Yang HJ; Xiang JQ; Zhang YW; Chen HQ
    BMC Cancer; 2015 May; 15():348. PubMed ID: 25934006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world outcomes of chemoradiotherapy for unresectable Stage III non-small cell lung cancer: The SOLUTION study.
    Horinouchi H; Atagi S; Oizumi S; Ohashi K; Kato T; Kozuki T; Seike M; Sone T; Sobue T; Tokito T; Harada H; Maeda T; Mio T; Shirosaka I; Hattori K; Shin E; Murakami H
    Cancer Med; 2020 Sep; 9(18):6597-6608. PubMed ID: 32730697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trimodality therapy for stage IIIA non-small cell lung cancer: benchmarking multi-disciplinary team decision-making and function.
    Dickhoff C; Hartemink KJ; van de Ven PM; van Reij EJ; Senan S; Paul MA; Smit EF; Dahele M
    Lung Cancer; 2014 Aug; 85(2):218-23. PubMed ID: 24976333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concurrent paclitaxel-based chemo-radiotherapy for post-surgical microscopic residual tumor at the bronchial margin (R1 resection) in non-small-cell lung cancer.
    Zhou M; Li T; Liu Y; Sun C; Li N; Xu Y; Zhu J; Ding Z; Wang Y; Huang M; Peng F; Wang J; Ren L; Lu Y; Gong Y
    BMC Cancer; 2015 Feb; 15():36. PubMed ID: 25655307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy.
    Koshy M; Malik R; Spiotto M; Mahmood U; Rusthoven CG; Sher DJ
    Lung Cancer; 2017 Jun; 108():222-227. PubMed ID: 28625640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy.
    Koo TR; Moon SH; Lim YJ; Kim JY; Kim Y; Kim TH; Cho KH; Han JY; Lee YJ; Yun T; Kim HT; Lee JS
    Radiat Oncol; 2014 Dec; 9():283. PubMed ID: 25498887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prognostic impact of supraclavicular lymph node in N3-IIIB stage non-small cell lung cancer patients treated with definitive concurrent chemo-radiotherapy.
    Oh D; Ahn YC; Park HC; Lim DH; Noh JM; Cho WK; Pyo H
    Oncotarget; 2017 May; 8(22):35700-35706. PubMed ID: 28415687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and safety of CT-guided (125)I seed brachytherapy for postoperative locoregional recurrence in patients with non-small cell lung cancer.
    Huo X; Wang H; Yang J; Li X; Yan W; Huo B; Zheng G; Chai S; Wang J; Guan Z; Yu Z
    Brachytherapy; 2016; 15(3):370-380. PubMed ID: 26944267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the efficacy of radiotherapy between postoperative mediastinal lymph node recurrence and stage III disease in non-small cell lung cancer patients.
    Imai H; Murakami H; Yoshino R; Mori K; Sumita K; Ono A; Akamatsu H; Taira T; Kenmotsu H; Harada H; Naito T; Kaira K; Tomizawa Y; Ohde Y; Matsuura M; Endo M; Saito R; Nakajima T; Takahashi T
    J BUON; 2016; 21(2):333-40. PubMed ID: 27273942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Definitive chemoradiation for locoregional recurrences of esophageal cancer after primary curative treatment.
    Jeene PM; Versteijne E; van Berge Henegouwen MI; Bergmann JJ; Geijsen ED; Muller K; van Laarhoven HW; Hulshof MC
    Dis Esophagus; 2017 Feb; 30(2):1-5. PubMed ID: 27766725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship Between Radiation Therapy Dose and Outcome in Patients Treated With Neoadjuvant Chemoradiation Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer: A Population-Based, Comparative Effectiveness Analysis.
    Sher DJ; Fidler MJ; Seder CW; Liptay MJ; Koshy M
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):307-16. PubMed ID: 25838187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors.
    Griffioen GH; Toguri D; Dahele M; Warner A; de Haan PF; Rodrigues GB; Slotman BJ; Yaremko BP; Senan S; Palma DA
    Lung Cancer; 2013 Oct; 82(1):95-102. PubMed ID: 23973202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy--retrospective analysis of 203 cases.
    Liu L; Bi N; Ji Z; Li J; Wang J; Wang X; Hui Z; Lv J; Liang J; Zhou Z; Wang Y; Yin W; Wang L
    BMC Cancer; 2015 Oct; 15():715. PubMed ID: 26474893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of pretreatment Glasgow prognostic score in stage IIIB geriatric non-small cell lung cancer patients undergoing radical chemoradiotherapy.
    Topkan E; Bolukbasi Y; Ozdemir Y; Besen AA; Mertsoylu H; Selek U
    J Geriatr Oncol; 2019 Jul; 10(4):567-572. PubMed ID: 31178158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concurrent chemoradiotherapy for patients with postoperative recurrence of surgically resected non-small-cell lung cancer.
    Takenaka T; Takenoyama M; Toyozawa R; Inamasu E; Yoshida T; Toyokawa G; Shiraishi Y; Hirai F; Yamaguchi M; Seto T; Ichinose Y
    Clin Lung Cancer; 2015 Jan; 16(1):51-6. PubMed ID: 25038000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.